YAP1 and in situ carcinoma: Interestingly, the strong setback in cell viability and enhanced levels of cleaved PARP (Fig. 5d, e), caused by macitentan and/or CIS treatments associated to β-arr1 or YAP depletion, was completely recovered by ectopic expression of β-arr1 or by the constitutively active YAP 5SA.